Podcast appearances and mentions of Johnson Johnson

"Until immunomodulators, patients [with myeloma] did not have a great overall survival rate. But when we introduced lenalidomide, we started seeing our patients have life expectancies between five and seven years—which was unheard of prior to these immunomodulators going forward. I think it's promising and allows patients to have quality of life versus therapy of life," ONS member Daniel Verina, DNP, RN, ACNP-BC, nurse practitioner for the multiple myeloma program at Mount Sinai Medical Center in New York, NY, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a conversation about immunomodulators. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 12, 2027. Daniel Verina is on the speakers' bureau for Johnson & Johnson, GlaxoSmithKline, and Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome:  Learners will report an increase in knowledge about the use of immunomodulators to treat cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 401: Multiple Myeloma Treatment Considerations for Oncology Nurses Episode 386: Interprofessional Navigation and the Oral Anticancer Medication Care Compass Episode 290: Cancer Symptom Management Basics: Peripheral Neuropathy ONS Voice articles: Maintain Oral Adherence With ONS Guidelines™ Multiple Myeloma Prevention, Screening, Treatment, and Survivorship Recommendations Sexual Considerations for Patients With Cancer Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum articles: Changes in Health-Related Quality of Life During Multiple Myeloma Treatment: A Qualitative Interview Study Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS book: Multiple Myeloma: A Textbook for Nurses (third edition) ONS Symptom Intervention resource: Peripheral Neuropathy Risk Evaluation and Mitigation Strategies (REMS) Lenalidomide Pomalidomide Thalidomide International Myeloma Foundation: Using Immune Therapy to Fight Multiple Myeloma International Myeloma Society Multiple Myeloma Research Foundation: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "We definitely want the diagnosis of multiple myeloma before initiating these drugs. We're going to look at serum protein electrophoresis. We want to make sure that we know the patient has serum free light chains and myeloma proteins to really confirm their disease. Plus, a bone marrow biopsy." TS 7:21 "Each immunomodulator has slightly different side effects. Thalidomide's biggest side effects are constipation, weakness, fatigue, somnolence, peripheral neuropathy, mood swings, hand tremors, and depression. With each generation, less of the side effects actually occurred. Most of lenalidomide's side effects, not discounting the deep vein thrombosis, are pancytopenia—the neutropenia, the anemia, and the thrombocytopenia. [The side effects] are very similar in pomalidomide." TS 15:40 "The REMS program is critical for oral immunomodulator therapies—thalidomide, pomalidomide, and lenalidomide. It was developed due to the risk of developing embryofetal toxicities. ... It is mandatory testing and counseling, so all females of reproductive potential must have two negative pregnancy tests prior to starting the therapy and then monthly pregnancy tests while on the therapy alone. Again, they must use two forms of effective contraceptives or abstain from heterosexual sex four weeks prior, during, and after. And the same thing for men. I focus on that because males may say, 'I have a vasectomy.' These therapies tend to bind to the semen. So, males must still use a latex or synthetic condom during any sexual contact with a female of reproductive potential, even if they did have a vasectomy." TS 18:31 "The capsule itself cannot be chewed, crushed, or opened. I bring that up because as healthcare professionals, we have educated our patients. If it's difficult to swallow capsules or tablets, we've always said to them, 'Oh, don't worry, just crush it into applesauce or open it up and sprinkle it on your mashed potatoes.' But because of this embryofetal toxicity, I advise my patients not to open the capsule. If they can't swallow it for any reason, they have a sore throat or they're just unable to, then [we tell them] to hold the therapy and then call us." TS 22:49 "We spoke about three generations already, but there's actually a fourth generation [of immunomodulators]. They're called cereblon E3 ligase modulators(CELMoDs). They're still in clinical trials but really showing promise in the therapy of myeloma. They're showing very good affinity to cereblons, just like the immunomodulators do. I think, in all cancer therapies, as newer generations come out or newer therapies move forward, some of the older generations might move aside, but they get integrated later on. So I don't think [immunomodulators] will disappear totally, but they will probably be modified." TS 36:39

What does resilience really look like? I meet many professionals today who are navigating wave after wave of change: Reorganisations, shifting priorities, business uncertainty, technological disruption and growing pressure to do more with less have become familiar features of organisational life. Yet while resilience is frequently talked about, it is often misunderstood. In this conversation with Julian Roberts, executive coach, author and host of the Helping Organisations Thrive podcast, we explore what resilience really means for leaders and teams operating in increasingly fragmented environments. After a 20-year career in senior roles at global organisations including Heinz, Yoplait and Johnson & Johnson, Julian founded Julian Roberts Consulting, specialising in helping leaders and teams thrive under pressure. He is the creator of the Team Resilience Diagnostic Tool and author of Weathering the Storm: A Guide to Building Resilient Teams. Together, we discuss why resilience is not about simply pushing through adversity, why 'grit' can sometimes become counterproductive, and how leaders can create the conditions for individuals and teams to navigate uncertainty more effectively. At the heart of this conversation is an important shift in perspective. Resilience is not a fixed trait that some people possess and others lack. It is a capability that can be developed, strengthened and intentionally cultivated, both individually and collectively. What you will learn in this episode: Why uncertainty and constant change are creating new leadership challenges for teams The difference between healthy resilience and what Julian describes as 'toxic resilience' Why resilience is not about simply working harder or pushing through difficulty Practical habits that help strengthen personal resilience, including gratitude, mindfulness and community How leaders can create greater resilience through purpose, meaning and clarity Why understanding the psychology of change helps leaders support people more effectively How diversity of thought strengthens a team's ability to navigate uncertainty and solve complex problems Why healthy challenge and critical thinking are essential leadership capabilities in today's workplace One of the strongest themes throughout this conversation is that resilience is not about individual toughness. Many organisations focus on helping individuals become more resilient, but resilient teams are created through something different. Purpose, trust, psychological safety, challenge, diverse perspectives and strong relationships all play a role in helping teams perform well under pressure. Ultimately, resilience is not about avoiding storms, it is about developing the capability to navigate them with greater clarity, adaptability and confidence. When faced with uncertainty, do you tend to push through harder, or create space to learn, reflect and adapt? What practices could help you strengthen your own resilience and support the resilience of those around you? Resources: Connect with Julian Roberts on LinkedIn: https://www.linkedin.com/in/julesroberts/ Learn more about Julian's book, 'Weathering the Storm': https://www.amazon.co.uk/dp/B0DFTYN2Y2 Listen to Julian Roberts' podcast: https://www.julianrobertsconsulting.com/podcast-1 Find out more about Victoria's leadership and Cultural Intelligence programmes: https://culturecuppa.com/individuals/ Learn more about and buy Victoria's book, Become a Global Leader: https://culturecuppa.com/book/ Follow Victoria on LinkedIn for more strategies, ideas and inspiration:https://www.linkedin.com/in/victoria-rennoldson

This episode covers: Cardiology This Week: A concise summary of recent studies Transcatheter treatment of tricuspid regurgitation Carcinoid heart disease Milestones: MADIT-II Trial Host: Wilfried Mullens Guests: Stephan Baldus, Heidi Connolly and Konstantinos Koskinas Want to watch that episode? Go to: https://esc365.escardio.org/event/2560 Want to watch that extended interview on transcatheter treatment of tricuspid regurgitation, go to: https://esc365.escardio.org/event/2560?resource=interview   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Heidi Connolly, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Wilfried Mullens Guest: Stephan Baldus Want to watch that extended interview, go to: https://esc365.escardio.org/event/2560?resource=interview Want to watch that entire episode? Go to: https://esc365.escardio.org/event/2560   Disclaimer ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Wilfried Mullens have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. Stephan Baldus has declared to have potential conflicts of interest to report: research grant from Abbott, lecture fees from Abbott and Edwards. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Is Nederland voor Johnson & Johnson nog wel het land om in te investeren voor nieuwe doorbraken? In ‘De top van Nederland’ een uitgebreid gesprek met Erik Holl, algemeen directeur van Johnson & Johnson Innovative Medicine Nederland. Presentator Nina van den Dungen vraagt hem of nieuwe Chinese innovaties een bedreiging zijn voor het verdienmodel? Over Johnson & Johnson Johnson & Johnson is een van de grootste farmaceutische en medische technologiebedrijven ter wereld. Het concern is onder meer actief in de ontwikkeling van geneesmiddelen en vaccins en heeft een belangrijke onderzoeks- en productielocatie in Leiden. Over Nina van den Dungen Thomas van Zijl is financieel journalist en presentator bij BNR. Hij presenteert dagelijks ‘BNR Zakendoen’, het Nederlandse radioprogramma voor economisch nieuws en zakelijk inzicht, waar 'De top van Nederland’ onderdeel van is. Ook is hij een van de makers van de podcast ‘Onder curatoren’. Abonneer je op de podcast Ga naar ‘De top van Nederland’ en abonneer je op de podcast, ook te beluisteren via Apple Podcast en Spotify. See omnystudio.com/listener for privacy information.

The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives.  Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock00:59 Remembering Mike stepping in during a past conference02:12 Mike reflects on filling in and returning to MacStock03:00 Speaker continuity and community expectations04:23 Staying healthy before the conference04:52 Mike introduces his workshop format05:12 Stepping into the role of a digital caretaker06:48 A Microsoft Office upgrade reveals a bigger issue08:39 A family member is caught by a Venmo scam09:19 Managing risks, passwords, and financial access10:11 Using built-in Apple tools instead of advanced services10:25 Safari, Chrome, verification codes, and Apple Passwords10:57 Setting up shared family password folders11:29 Defining digital caretaking12:39 The family “alpha nerd” becomes responsible14:11 Remote tech support challenges and FaceTime troubleshooting16:01 Asynchronous support, screenshots, and remote access tools17:57 Older adults as prime targets for scammers18:53 AARP, Craig Newmark, and scam-interruption resources19:51 Gift cards, retail workers, and scam warning signs20:35 Deepfakes, safe words, and trusted contacts21:40 Fake profiles and stolen valor scams22:48 Protecting family members from criminal targeting23:25 Romance scams, business scams, and phishing tactics25:02 Keeping loved ones safe without burning out26:09 The Beekeeper as a scam-awareness example27:07 Recommended resources and My Mother's Money28:18 Financial preparedness and how quickly gaps appear29:39 Using AI tools to find validated resources30:18 Why this workshop may matter to everyone31:02 The future reversal of helper and helped33:00 Balancing safety, respect, and autonomy34:00 Managing support while preserving dignity36:23 Mike's MacStock discount code37:01 Registering for MacStock and planning ahead38:14 Where to find Mike T. Rose and The Aftershow39:29 Mike's social channels and listener acknowledgments40:17 Remembering John Martellaro and Chuck La Tournous41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s.Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce.Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support:      Become a MacVoices Patron on Patreon     http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:     http://macvoices.com      Twitter:     http://www.twitter.com/chuckjoiner     http://www.twitter.com/macvoices      Mastodon:     https://mastodon.cloud/@chuckjoiner      Facebook:     http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:     http://www.facebook.com/macvoices/      MacVoices Group on Facebook:     http://www.facebook.com/groups/macvoice      LinkedIn:     https://www.linkedin.com/in/chuckjoiner/      Instagram:     https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes     Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

The Road to Macstock takes a serious turn as Mike T. Rose previews his workshop on becoming a digital caretaker for family members and loved ones. Mike discusses scams targeting older adults, password sharing, remote support, Apple Passwords, financial preparedness, and the need to balance protection, respect, independence, and trust when helping others manage their digital lives.  Today's edition of MacVoices is supported by MacVoices Live!, our weekly live panel discussion of what is going in the Apple space as well as the larger tech world, and how it is impacting you. Join us live at YouTube.com/MacVoicesTV at 8 PM Eastern 5 PM Pacific, or whatever time that is wherever you are and participate in the chat, or catch the edited and segmented versions of the show on the regular MacVoices channels and feeds. Show Notes: Chapters: 00:00 Introduction to Mike T. Rose on the Road to Macstock 00:59 Remembering Mike stepping in during a past conference 02:12 Mike reflects on filling in and returning to MacStock 03:00 Speaker continuity and community expectations 04:23 Staying healthy before the conference 04:52 Mike introduces his workshop format 05:12 Stepping into the role of a digital caretaker 06:48 A Microsoft Office upgrade reveals a bigger issue 08:39 A family member is caught by a Venmo scam 09:19 Managing risks, passwords, and financial access 10:11 Using built-in Apple tools instead of advanced services 10:25 Safari, Chrome, verification codes, and Apple Passwords 10:57 Setting up shared family password folders 11:29 Defining digital caretaking 12:39 The family "alpha nerd" becomes responsible 14:11 Remote tech support challenges and FaceTime troubleshooting 16:01 Asynchronous support, screenshots, and remote access tools 17:57 Older adults as prime targets for scammers 18:53 AARP, Craig Newmark, and scam-interruption resources 19:51 Gift cards, retail workers, and scam warning signs 20:35 Deepfakes, safe words, and trusted contacts 21:40 Fake profiles and stolen valor scams 22:48 Protecting family members from criminal targeting 23:25 Romance scams, business scams, and phishing tactics 25:02 Keeping loved ones safe without burning out 26:09 The Beekeeper as a scam-awareness example 27:07 Recommended resources and My Mother's Money 28:18 Financial preparedness and how quickly gaps appear 29:39 Using AI tools to find validated resources 30:18 Why this workshop may matter to everyone 31:02 The future reversal of helper and helped 33:00 Balancing safety, respect, and autonomy 34:00 Managing support while preserving dignity 36:23 Mike's MacStock discount code 37:01 Registering for MacStock and planning ahead 38:14 Where to find Mike T. Rose and The Aftershow 39:29 Mike's social channels and listener acknowledgments 40:17 Remembering John Martellaro and Chuck La Tournous 41:22 Final Macstock encouragement and wrap-up Guests: Mike Rose is a past Macstock speaker and multi-year attendee. He is an occasional podcaster with fellow Macstock speaker Kelly Guimont at aftershowpodcast.com, continuing their collaboration from the much-missed TUAW.com (The Unofficial Apple Weblog) in the 2000s and 2010s. Mike began his technology career at the dawn of the desktop publishing revolution, helping transform workflows and introduce the Mac at Entertainment Weekly and LIFE magazines in the 1990s. After his second career in the event production and sales training industry (working with clients such as Pfizer, Dell, AstraZeneca, Johnson & Johnson, and Deloitte), he pivoted to enterprise software in 2013 and is now a Senior Director of Solution Engineering at Salesforce. Outside of work, Mike is active in an NYC community choir, and supports his wife Heidi's congregation as a volunteer technology, AV and operations consultant. Mike & Heidi live in Brooklyn, NY with their two young adult daughters and one young adult cat. Catch him on The Aftershow with Kelly Guimont. Support:      Become a MacVoices Patron on Patreon      http://patreon.com/macvoices      Enjoy this episode? Make a one-time donation with PayPal Connect:      Web:      http://macvoices.com      Twitter:      http://www.twitter.com/chuckjoiner      http://www.twitter.com/macvoices      Mastodon:      https://mastodon.cloud/@chuckjoiner      Facebook:      http://www.facebook.com/chuck.joiner      MacVoices Page on Facebook:      http://www.facebook.com/macvoices/      MacVoices Group on Facebook:      http://www.facebook.com/groups/macvoice      LinkedIn:      https://www.linkedin.com/in/chuckjoiner/      Instagram:      https://www.instagram.com/chuckjoiner/ Subscribe:      Audio in iTunes      Video in iTunes      Subscribe manually via iTunes or any podcatcher:      Audio: http://www.macvoices.com/rss/macvoicesrss      Video: http://www.macvoices.com/rss/macvoicesvideorss

This Day in Legal History: The Indian Citizenship Act of 1924On this day in 1924, President Calvin Coolidge signed the Indian Citizenship Act, also called the Snyder Act, declaring that all Native Americans born within the territorial limits of the United States were U.S. citizens. It is one of those laws that sounds, in retrospect, like it cannot possibly have been necessary — and yet it was. For most of the country's first 150 years, the federal government treated Native people as members of separate sovereign nations whose status under American law was, at best, ambiguous. Earlier vehicles for citizenship — the Fourteenth Amendment, the Dawes Act, military service in World War I — had reached only some Native people, and a string of Supreme Court decisions had taken the position that being born inside the United States to a member of a tribe did not, on its own, make a person a citizen.The Snyder Act fixed that with a single sentence.What it did not fix was voting: many states continued to bar Native citizens from the ballot for decades afterward, on a variety of pretexts that were eventually struck down one by one. The Act also did not affect tribal citizenship — Native people are dual citizens of their tribe and the United States, which is part of why federal Indian law continues to occupy a separate doctrinal universe. June 2 is a quietly important date on the calendar of American citizenship, and a reminder that the seemingly obvious questions of who counts as an American have, for long stretches of our history, not been obvious at all.Florida Attorney General James Uthmeier announced Monday that his office has filed a civil lawsuit against OpenAI and its CEO Sam Altman, arguing that the company is misleading parents about the safety of ChatGPT and pointing to incidents in which young users were allegedly nudged toward violence by the chatbot. The complaint follows a criminal investigation Uthmeier's office opened in April, after a deadly mass shooting at Florida State University in 2025 that the AG says ChatGPT helped facilitate. Florida is asking for civil penalties and an order forcing OpenAI to redesign the product, including adding meaningful parental controls.The legal angle here is essentially a state consumer-protection theory: a state attorney general claiming that the company's marketing of a product as safe-for-kids is deceptive, and that the company is therefore on the hook under the state's unfair-trade laws. Whether that survives a motion to dismiss is going to depend a lot on whether the court treats ChatGPT as a “product” in the traditional sense — software has, for decades, gotten more leeway than physical products under product-liability law, and Section 230 of the federal Communications Decency Act has historically immunized platforms for what users post.The new wrinkle is that generative AI doesn't fit neatly into either bucket — ChatGPT produces its own output rather than hosting somebody else's — and several courts are now beginning to grapple with that distinction. Expect this case to be one of the early test cases for how AI companies get sued in the U.S.Florida AG Sues OpenAI, Says ChatGPT Spurs Violence | Law360The Supreme Court on Monday declined to hear an appeal from asbestos victims who had challenged a corporate bankruptcy tactic known as the “Texas Two-Step” — leaving in place a Fourth Circuit ruling that lets companies use the maneuver to corral mass-tort claims into bankruptcy court.The Two-Step works like this: a healthy company splits itself into two using a Texas state-law provision that allows divisional mergers, dumps its asbestos or talc or opioid liabilities into the newly created spinoff, and then puts only the spinoff into Chapter 11. The result is that injury claimants get herded into a bankruptcy proceeding where their leverage is sharply limited, even though the parent company that actually caused the harm is still solvent and operating.The case the Supreme Court turned away involved Bestwall, a spinoff of Georgia-Pacific that has been in Chapter 11 since 2017. The Third Circuit threw out a similar Johnson & Johnson talc-unit bankruptcy in 2023 on the ground that the spinoff wasn't actually in financial distress, but the Fourth Circuit went the other way in this case, and the Supreme Court's denial of review leaves that split standing for now. The bigger picture: a powerful settlement-shaping tool stays on the menu for corporate defendants facing waves of mass-tort litigation, and the next big talc, opioid, or asbestos defendant looking to manage a docket of claims now knows the Two-Step is at least available in the Fourth Circuit.Justices Won't Hear Challenge To ‘Texas Two-Step' Ch. 11 | Law360A group of IKEA customers filed a proposed class action against the Swedish retailer Monday in U.S. federal court, arguing that they overpaid for furniture during the period when President Trump's import tariffs were in effect — tariffs that the Supreme Court has since struck down — and that they are entitled to a share of the refunds the company will now collect from the federal government. It is one of the first big consumer-side cases to follow the Supreme Court's tariff ruling, and the legal theory is novel: importers paid the tariffs, then passed those costs through to consumers in the form of higher sticker prices, and now that the government is sending refunds back to importers, the customers who effectively bore the cost are asking for a piece of that money.Some major shippers like FedEx and UPS have already publicly committed to passing tariff refunds back to their customers; IKEA, the suit alleges, has not. Whether the claim survives depends largely on whether the court is willing to treat the relationship between retailer and customer as something like a constructive trust or unjust enrichment, rather than an arm's-length sale at a final price. If even one of these cases succeeds, expect copycat suits against every other large importer that quietly built tariff costs into retail prices over the last several years.IKEA customers sue for share of Trump tariff refunds | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe

Eric Ries is the entrepreneur and author of The Lean Startup, whose work helped software founders validate ideas faster and build companies without making huge bets upfront. After years helping startups, large companies, and governments apply Lean Startup principles, Eric built the Long-Term Stock Exchange and turned his attention to a bigger question: Why do so many successful companies lose their way?   In our conversation, Eric explains the idea of "financial gravity"—the hidden force that pushes companies toward short-term financial thinking as they grow. He shares cautionary stories of companies like Whole Foods, Johnson & Johnson, Silicon Valley Bank, and Costco to show how scaling, investors, boards, and even employees can gradually erode trust, mission, and long-term value.   Eric's new book, Incorruptible Why Good Companies Go Bad…and How Great Companies Stay Great, offers practical ways founders can protect the soul of their companies before it's too late--even when they don't have big outside investors. He explains why founders should explicitly codify their mission into governance structures, why trust is the most underrated asset in business, and how practical founders can retain optionality while building valuable companies that endure. Drawing on two decades of work with founders, CEOs, and investors, Eric Ries reveals the forces that make companies vulnerable to destruction from within and without. Then he offers solutions that safeguard against them for the long-term. Incorruptible is the blueprint for companies that will prosper and endure without losing their soul. Key Takeaways Financial Gravity - Every growing company faces pressure toward short-term financial thinking—even without outside investors. Trust Compounds - Companies that earn trust with customers and employees often outperform financially over the long term. Founder Regret - Many founders regret selling because the mission, culture, and soul of the company disappear. Mission Protection - Values on a wall aren't enough—founders need legal and governance structures to preserve mission. Question Best Practices - Many accepted business practices optimize short-term profits while destroying long-term value. Think Long-Term - Practical founders have more optionality when they intentionally design companies to endure. Quote from Eric Ries, Author of the Lean Startup "People have woken up to this reality. Given where we're at, if you can create a bootstrap company, if you can maintain control, it doesn't make you completely safe. The problem is actually not investors, but financial thinking.  "So I tell a bunch of stories in my book (Incorruptible)  of companies where the issue wasn't investors, but their own employees. You start to bring in professional managers. You start to bring in a CFO, and the CFO has that extractive mindset, or even worse. "Financial gravity is one of the most underrated concepts in business. It is like trying to direct our attention away from the surface characteristics of an organization to the deeper forces that act on it. Your  business model, strategy, vision, culture, these things are very important, but they are the things that we have control over. Financial gravity is a force." Links Eric Ries on LinkedIn Eric Ries on Twitter Eric Ries Podcast Incorruptible book on Amazon Podcast Sponsor – Lighter Capital This podcast is sponsored by Lighter Capital. In the last 15 years, Lighter Capital has helped over 600 software and SaaS founders secure simple, non-dilutive financing to grow a little faster—without giving up any precious equity or board seats to investors.  Simple debt funding from Lighter Capital can range from $50K to $10 million, with straightforward terms, no personal guarantees or covenants, and up to a 4-year payback period. Go to LighterCapital.com to apply and get a quick pre-qualification. Then talk with their experienced team to create a practical funding plan to achieve your goals.  The Practical Founders Podcast Tune into the Practical Founders Podcast for weekly in-depth interviews with founders who have built valuable software companies without big funding. Subscribe to the Practical Founders Podcast using your favorite podcast app or view on our YouTube channel. Get the weekly Practical Founders newsletter and podcast updates at practicalfounders.com. Practical Founders CEO Peer Groups Be part of a committed and confidential group of practical founders creating valuable software companies without big VC funding.  A Practical Founders Peer Group is a committed and confidential group of founders/CEOs who want to help you succeed on your terms. Each Practical Founders Peer Group is personally curated and moderated by Greg Head.

One of the largest mass tort litigations in U.S. history is heating up, and this episode breaks down exactly what you need to know. From the collapse of Johnson & Johnson's third bankruptcy attempt to the current push for bellwether trials and remands, attorney Cameron Stephenson of Levin Papantonio gives a candid, insider look at where the talc litigation stands and what plaintiffs, attorneys, and affected individuals can expect in the months ahead. Host Greg is joined by Cameron to unpack the science behind asbestos contamination in talc, the latency period for ovarian cancer and mesothelioma diagnoses, why J&J's litigation tactics have drawn fierce criticism, and what a realistic path to settlement actually looks like.   Join Gregg and Cameron on Cut to the Chase as they explore: Why J&J's three bankruptcy attempts were rejected and what that means for plaintiffs The science behind asbestos in talc and how it causes ovarian cancer and mesothelioma What "latent disease" means and why recent diagnoses can still qualify for claims How the MDL remand process works and why it matters for case resolution The current state of state court trials and why plaintiffs have been winning Why J&J attacked Beasley Allen — and what it reveals about their litigation strategy   KEY MOMENTS Intro: Talc mass tort litigation overview Post-bankruptcy update: Back in the MDL How the 3 bankruptcies froze all cases Bellwether trial target: Q3/Q4 + active state court cases Can recently diagnosed patients still file? What is a latent disease & why it matters The asbestos-talc connection explained How asbestos gets into talcum powder (the mining process) J&J's defense vs. the evidence against them MDL, remand & Daubert explained in plain English Wave remand strategy: How to pressure J&J Why plaintiffs' attorneys need to coordinate now The $8.9B offer and why it wasn't enough Hope for plaintiffs: Strong science, angry juries How to contact Cameron Stevenson The attack on Beasley Allen, J&J's scorched earth tactics Closing: Don't wait, justice is coming   Cameron Stephenson is an attorney at Levin Papantonio, one of the country's leading plaintiffs' litigation firms. With a track record of significant courtroom victories, Cameron holds leadership positions in several of the largest mass tort litigations in the U.S., including the talc/ovarian cancer MDL and the Ozempic litigation. Stephenson is an active advocate for coordination among plaintiffs' counsel in the talc litigation, offering trial school resources, deposition packages, and case preparation support to attorneys across the country.   Contact Cameron Stephenson: Phone: (850) 435-7176 Email: cstephenson@levinlaw.com Website: https://levinlaw.com/   Want more insights on leadership, crisis, and the decisions that define careers and companies? Subscribe to Cut to the Chase with Gregg Goldfarb for new episodes every week.

Host: Rick Grobbee Guest: Kristina Haugaa Want to watch that extended interview on https://esc365.escardio.org/event/2563?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2563   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies The heart in high altitude Mitral annular disjunction Mythbusters: Weekend mortality Host: Rick Grobbee Guests: JP Carpenter, Kristina Haugaa, Silvia Ulrich Want to watch that episode? Go to: https://esc365.escardio.org/event/2563 Want to watch that extended interview on mitral annular disjonction, go to: https://esc365.escardio.org/event/2563?resource=interview   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Rick Grobbee, Kristina Haugaa, Nicolle Kraenkel and Silvia Ulrich have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This week, we revisit our conversation with Rich Ferrari. Rich is a seasoned healthcare entrepreneur and investor with a track record of building and scaling medical device and biotech companies. He is a Co-Founder of De Novo Ventures, a premier life sciences venture firm that managed $650M, and has helped raise over $1B in capital while contributing to nearly $1.8B in successful acquisitions. Most recently, Rich served as CEO and Chairman of PQ Bypass, leading to its $350M acquisition by Endologix. He has also led and exited multiple companies, including Cardiovascular Imaging Systems (acquired by Boston Scientific) and CardioThoracic Systems (acquired by Guidant), where he drove one of the fastest IPOs in medtech history. A prolific founder, Rich has co-founded several successful ventures acquired by major players like Johnson & Johnson, Abbott, and Medtronic. He currently serves on multiple boards, including Tenon Medical (NASDAQ: TNON), HeartBeam, and Medlumics. Rich holds a BS from Ashland University and an MBA from the University of South Florida, and is a recipient of the Mallinckrodt Award for Excellence in Medicine.

His Boss Told Him He'd Never Rise Above Engineer Level. Three Years Later, That Boss Reported to Him. Samuel Santos on Getting Noticed at Work Early in his career, his manager told him the company had a prototype for success: blonde hair, green eyes. Samuel Moody Santos was mixed race, Black, an immigrant who had started his working life as a waste picker. His manager told him he would never advance past engineer level. Three years later, Samuel was a manager and that man reported to him. He went on to retire as Senior Vice President at Johnson & Johnson, one of the top 40 Fortune 500 companies in the world. He speaks five languages. He holds an engineering degree and an MBA. And he wrote the book on how he did it: "In Spite of the Headwinds." In this episode, Samuel shares the specific mindset shifts, communication strategies, and career moves that took him from invisible to indispensable, as a minority, an immigrant, and someone who was actively told he didn't belong. You'll learn: Why "success depends on who you know" is the wrong mental model, and the one-sentence reframe Samuel used to challenge a corporate trainer in a room of 40 people that changed how he thought about visibility for the rest of his career. Why doing excellent work and staying quiet about it is the same as doing nothing, and how he marketed his ideas without ever bragging about himself. How he turned a direct manager who tried to limit his career into a stepping stone by building relationships with leaders two and three levels above that manager. The "poor photograph" framework: why being visible without being skilled fails, and why being skilled without being visible fails just as badly. Why he treats every "no" the same way: either he didn't explain the idea well enough, or he needs a different audience. The Starbucks founder knocked on 242 doors. Samuel applied that same logic to ideas inside a corporation. How he disagrees with superiors without triggering defensiveness: "I never disagree with any person. I disagree with ideas." The specific language he used to pose challenges as questions so people moved toward his position instead of defending against it. The performance review confrontation where someone tried to penalize a team member for a mistake from two years prior, and how Samuel addressed the entire room to win that argument on the spot. Why he focused ruthlessly on the one skill he could take above average (presenting technical ideas to non-technical executives), and chose not to develop things that wouldn't move the needle, including declining to learn Mandarin during a two-year assignment in Shanghai. About Samuel Moody Santos: Retired Senior Vice President at Johnson & Johnson, Samuel is an engineer, MBA, minister, polyglot (five languages), honorary consul, former university professor, public speaker, and author of "In Spite of the Headwinds: My Journey from Waste Picker to Vice President at a Top-Forty Fortune 500 Company." Book: https://www.amazon.com/Spite-Headwinds-Picker-Senior-Executive-ebook/dp/B09KGRQ61W Connect with Samuel on LinkedIn: https://www.linkedin.com/in/samuel-moody-santos-56601a10/

In this episode, host Shikha Jain, MD, speaks with Jessica MacIntyre, DNP, about her role and goals as president of the Oncology Nursing Society, multidisciplinary focuses within cancer care and more. ·       Welcome to another exciting episode of Oncology Overdrive 1:22 ·       About Jessica MacIntyre, DNP, MBA, APRN, AOCNP, FAANP 1:34 ·       The interview 2:50 ·       Tell me about how you got to where you are today […] What was your journey to becoming a nurse practitioner, and into the leadership role you hold today? 3:15 ·       What is Oncology Nursing Society (ONS)? What does it do, and how did you become president?  5:17 ·       What are your goals as president of ONS? 9:08 ·       Jain and MacIntyre on the importance of multidisciplinary approaches to cancer care. 12:28 ·       What excites you about the role of nurses and nurse practitioners, and the future of the oncology team as a whole? 14:34 ·       Where do you see the future of patient navigation going? […] Where do you see AI playing a role in all of this? 17:42 ·       What do you say to people who are scared of AI becoming all-encompassing? 20:41 ·       Jain and MacIntyre on embracing and improving the use of AI in cancer care. 22:14 ·       What do you recommend to nurses as they embark on their careers? […] How can we make sure nurses are working to the top of their license while supporting the cancer care team? 24:09 ·       Jain and MacIntyre on the increasing importance of advocacy in health care. 26:55 ·       If someone could only listen to the last minute of this episode, what would you want listeners to take away? 28:31 ·       How to contact MacIntyre 30:00 ·       Thanks for listening 30:56 Jessica MacIntyre, DNP, MBA, APRN, AOCNP, FAANP, is president of the Oncology Nursing Society and executive director of clinical operations at Sylvester Comprehensive Cancer Center, part of University of Miami Miller School of Medicine. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. MacIntyre can be reached on LinkedIn, or via email jmacintyre@med.miami.edu. Jain reports no relevant financial disclosures. MacIntyre reports compensation from Johnson & Johnson for participation on a nursing panel.

This episode covers: Cardiology This Week: A concise summary of recent studies Biomarkers in heart failure Digoxin in HFrEF Scientific Highlights from Heart Failure 2026 Host: Wilfried Mullens Guests: Lynne Stevenson, Dirk van Veldhuisen, Theresa McDonagh Want to watch that episode? Go to: https://esc365.escardio.org/event/2565 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. A ny views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel, Dirk van Veldhuisen and Lynne Warner Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report:Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi.  Theresa McDonagh has declared to have potential conflicts of interest to report: honoraria from Boeringer Ingelheim. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this episode of the Medical Sales Podcast, Samuel Adeyinka sits down with Jason Brooks to unpack his journey from serving as a Navy hospital corpsman and working alongside Marines in Iraq to building a successful career across surgical devices, capital equipment, genetic testing, and biotech. Jason shares how his early medical training, military leadership experience, and business background helped him break into medical sales with Johnson & Johnson, what it took to navigate the interview process, and how one career changing offer reshaped his future. He also breaks down the differences between selling in the operating room and selling genetic testing into clinics and hospital systems, why reps need to understand stakeholders beyond the physician, and how culture, strategy, and persistence can define long term success in the industry. This episode is a must listen for anyone looking to break into medical sales, transition between specialties, or understand what it really takes to build a meaningful career in the field. Connect with Jason Brooks: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How »

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/WNB865. CME/AAPA credit will be available until April 21, 2027.A New Era in Psoriasis Care With Oral IL-23 Inhibitors In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

What keeps organizations from getting the innovation they say they want? In this episode, Kevin talks with Lorraine Marchand about why innovation so often stalls inside teams and organizations, even when leaders claim it is a top priority. Lorraine explains that the real barrier is not a lack of ideas, but a culture that punishes failure instead of treating it as experimentation and learning. They discuss the gap between intention and action, the different types of organizational innovation mindsets, and the leadership practices that help create environments where people feel safe to contribute, test, and grow. Lorraine also shares the five principles that support sustainable innovation (culture, customer focus, chance, collaboration, and change), offering practical insight for leaders at the organization level and the individual level. Listen For 00:00 Why We Want Innovation But Don't Get It 02:57 The Big Idea Behind the Book 04:08 Why Innovation Breaks Down 07:00 The 4 Types of Organizations 12:02 What This Means for Team Leaders 14:09 Why Leaders Rush to Solutions 15:32 Creating Psychological Safety 19:07 The 5 C's of Innovation 23:27 The Truth About "Customer First" 26:27 The Role of Risk in Innovation 30:01 Final Advice on Taking Initiative 31:09 What Lorraine Is Reading 32:42 Where to Connect 33:31 The Most Important Question: Now What? 33:51 Closing Thoughts Lorraine's Story: Lorraine H. Marchand is the author of the new book No Fear No Failure: Five Principles for Sustaining Growth Through Innovation. She is an acclaimed consultant, author, and educator on innovation with extensive experience in new product development. She has cofounded several start-ups; held leadership positions at companies including Bristol-Myers Squibb, Covance/LabCorp, and IBM; and served as advisor to Johnson & Johnson and Hewlett Packard. Marchand is the author, with John Hanc, of The Innovation Mindset: Eight Essential Steps to Transform Any Industry. She serves on the boards of several privately held companies and the Healthcare and Pharmaceutical Advisory Board at Columbia Business School, and she teaches at the Wharton School and Yeshiva University. https://www.lorrainemarchand.com/ https://www.linkedin.com/in/lorrainemarchand/ Looking to Develop Stronger Leaders? Want help developing the leaders in your organization? Reach out to explore how the Kevin Eikenberry Group can support your team at info@kevineikenberry.com.  Book Recommendations No Fear, No Failure: Five Principles for Sustaining Growth Through Innovation by Lorraine Marchand and John Hanc The Innovation Mindset: Eight Essential Steps to Transform Any Industry by Lorraine Marchand and John Hanc Invisible Women: Data Bias in a World Designed for Men by Caroline Criado Perez Like this? The Innovation Stack with Jim McKelvey The Human Side of Innovation with Mauro Porcini Where Creativity Meets Innovation with Deepak Ohri Join Our Community If you want to view our live podcast episodes, hear about new releases, or chat with others who enjoy this podcast join one of our communities below. Join the Facebook Group Join the LinkedIn Group   Podcast Better! Sign up with Libsyn and get up to 2 months free! Use promo code: RLP   Leave a Review If you liked this conversation, we'd be thrilled if you'd let others know by leaving a review on Apple Podcasts. Here's a quick guide for posting a review. Review on Apple: https://remarkablepodcast.com/itunes   

Helayna Minsk is an experienced executive leader who has led major organizational transformation for brands like Unilever, Walgreens, and Johnson & Johnson. Helayna's work encompasses general management, P&L leadership, portfolio evolution, and revitalization campaigns, both domestically and internationally. Her approach to brand stewardship and cross-functional collaboration has led to an extensive track record of profit expansion, scalable growth, and strategic implementation for some of the largest CPG companies in the world. Helayna joins Roy to discuss leadership lessons learned during periods of immense change, how communication is the cornerstone of high-performance teams, the upside of ambition, and much more. Highlights from our conversation include: - Core values that have become part of Helayna's leadership playbook (3:07) - Mentors and learning opportunities that helped shape her leadership philosophy (5:16) - How Helayna's leadership developed and evolved as she took on different roles (7:44) - The role talent plays in driving growth and impact (10:17) - Tips for navigating changing market dynamics and consumer behavior (14:10) - How Helayna developed an aptitude for hiring top performers and building high performance teams (16:05) - Comparing the approach to talent and hiring at different brands (18:25) - What Helayna looks for when she's hiring for her own leadership teams (20:09) - How she approached leading a turnaround for J&J in China (22:17) - Cultural differences when working in China that adapted her thinking -(25:27) - Advice Helayna has for people early in their careers (28:33) - What's next for Helayna (30:29)

At the inaugural ACCC Leadership Summit, C-suite executives and senior-level decision makers in oncology convened for strategic dialogue, engaging panel discussions, and peer-to-peer exchange focused on the most pressing issues in cancer care today. In this episode, CANCER BUZZ speaks with Michele LeSueur, DBA, vice president of Sales and Marketing at Johnson & Johnson, about her key takeaways as a member of the final panel of the Summit: Strategic Partnerships: Creating a Thriving Innovation Oncology Ecosystem. Across the diverse panel of stakeholders, one theme consistently rang true: Innovation is happening very quickly in oncology, but the gap continues to widen between the inception and the implementation of these ideas into day-to-day patient care. Lesueur also comments on the importance of industry partners listening and understanding where friction might occur when launching a new treatment or delivery system. "It's not just about continuously generating breakthrough science or breakthrough treatment. That's only going to take us so far. We have to think about how to actually incorporate that and get it to the patients." – Michele LeSueur, DBA Guest: Michele LeSueur, DBA Vice President of Sales and MarketingJohnson & Johnson Resources: 2026 ACCC Leadership Summit Innovation, Policy, and Partnership: Key Takeaways From the Inaugural ACCC Leadership Summit One Purpose, One Passion, 2 Directions: How to Bring Together Clinical and Administrative Leaders

Host: Wilfried Mullens Guest: Marc Dweck Want to watch that extended interview on https://esc365.escardio.org/event/2564?resource=interview Go to: Want to watch that episode? Go to: https://esc365.escardio.org/event/2564   Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Genetics and genetic testing in HCM Asymptomatic aortic valve stenosis Statistics Made Easy: Mediation analysis Host: Wilfried Mullens Guests: JP Carpenter, Caroline Coats, Marc Dweck Want to watch that episode? Go to: https://esc365.escardio.org/event/2564 Want to watch that extended interview on asymptomatic aortic valve stenosis, go to: https://esc365.escardio.org/event/2564?resource=interview   Disclaimer  ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails.  ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.    Declarations of interests Stephan Achenbach, Yasmina Bououdina, Antonio Greco and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Caroline Coats has declared to have potential conflicts of interest to report: in the last 5 years, consultant/advisor to Bayer, Bristol Myers Squibb, Cytokinetics, Sanofi, Roche Diagnostics. Marc Dweck has declared to have potential conflicts of interest to report: consultancy fees from Novartis, Silence, and AstraZeneca related to aortic stenosis and development of a medical therapy. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Can you take a clean beauty brand built on accessibility — and evolve it into a global “everyday luxury” powerhouse without losing what made it special? On today's episode, we welcome Michael Marquis, CEO of Raw Sugar Living — the personal care brand known for bringing clean, high-quality products to the masses at an accessible price point. With more than 30 years of experience across global consumer giants like Johnson & Johnson — where he led iconic brands including Listerine, Clean & Clear, and OGX — Michael brings a unique combination of operational discipline and brand-building expertise to Raw Sugar's next chapter. Since joining the company in 2022, Michael has led Raw Sugar through a period of rapid growth and transformation, expanding distribution across major retailers like Target, Walmart, and CVS while strengthening the brand's foundation in clean, vegan-friendly formulations and its signature design. Now, he's guiding the company through a major evolution — reimagining the brand with updated packaging, improved formulas, and a sharper positioning around “accessible everyday luxury.” In this episode, Michael shares what it takes to execute a thoughtful rebrand without alienating loyal customers, how to build and sustain strong retail partnerships, and why operational excellence is critical when scaling in a competitive category. We also discuss the evolution of the clean beauty market, shifting consumer expectations around transparency and ingredients, and how leadership — including his perspective as a father — shapes both company culture and long-term strategy. If you're interested in scaling consumer brands, navigating rebrands, or building products that balance quality, accessibility, and growth — this episode is for you. Tune in now on The Kara Goldin Show.   Are you interested in sponsoring and advertising on The Kara Goldin Show, which is now in the Top 1% of Entrepreneur podcasts in the world? Let me know by contacting me at karagoldin@gmail.com. You can also find me @‌KaraGoldin on all networks.   To learn more about Michael Marquis and Raw Sugar:https://www.rawsugarliving.comhttps://www.instagram.com/rawsugarliving/https://www.linkedin.com/in/michaelmarquis/   Sponsored By: LinkedIn Jobs - Head to LinkedIn.com/KaraGoldin to post your job for free. AT&T Business - Switch to AT&T Business at business.att.com   Check out our website to view this episode's show notes: https://karagoldin.com/podcast/831

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FZN865. CME credit will be available until April 8, 2027.Optimizing MDD Management in Primary Care: Advancing Patient Outcomes Through Better Assessment and Team-Based Solutions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FZN865. CME credit will be available until April 8, 2027.Optimizing MDD Management in Primary Care: Advancing Patient Outcomes Through Better Assessment and Team-Based Solutions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FZN865. CME credit will be available until April 8, 2027.Optimizing MDD Management in Primary Care: Advancing Patient Outcomes Through Better Assessment and Team-Based Solutions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FZN865. CME credit will be available until April 8, 2027.Optimizing MDD Management in Primary Care: Advancing Patient Outcomes Through Better Assessment and Team-Based Solutions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/NBP865. CME/NCPD/AAPA credit will be available until April 18, 2027.Sorting the Sequence in Multiple Myeloma: Personalized Choices With BCMA and Non-BCMA Immunotherapies in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from Arcellx, Inc. and Kite, a Gilead Company; AstraZeneca; Johnson & Johnson; and Legend Biotech.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FZN865. CME credit will be available until April 8, 2027.Optimizing MDD Management in Primary Care: Advancing Patient Outcomes Through Better Assessment and Team-Based Solutions In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Johnson & Johnson.Disclosure information is available at the beginning of the video presentation.

In a wide-ranging interview, Dr. Sylvain Charlebois ("The Food Professor") discusses whether lab-grown (cellular) meat is overhyped, citing consumer acceptance, cost, and labeling as key barriers, though he found lab-grown chicken indistinguishable in taste and notes potential for nutrient customization. The conversation then turns to Canadian food inflation, arguing there is little evidence grocers are gouging consumers via higher margins, though grocers pressure suppliers through fees, affecting prices and supply-chain discipline. Charlebois contends food inflation is largely structural and policy-driven, pointing to trade barriers, carbon tax impacts, logistics, supply management, counter-tariffs, and the GST holiday's inflationary effect. He proposes solutions focused on competition, tax relief, logistics investment, and policy reform, and closes with a cautious view of ultra-processed food rhetoric, emphasizing consumer information over bans.   Dr. Sylvain Charlebois is a professor of food distribution and policy at Dalhousie University and director of the Agri-Food Analytics Lab, where his work focuses on food distribution, food policy, food security, and food safety. Widely known as "The Food Professor," he is one of Canada's most recognized voices on food inflation, grocery pricing, supply chains, and the future of food. His research has been featured in major outlets including The Economist, The New York Times, The Wall Street Journal, and The Globe and Mail, and he also hosts The Food Professor Podcast. In this episode, he breaks down what's really driving food prices in Canada, whether grocers are being unfairly blamed, the debate around lab-grown meat, and how ultra-processed foods and GLP-1 drugs are reshaping the food industry.   Sylvain / The Food Professor The Food Professor on X — https://x.com/FoodProfessor Sylvain Charlebois on LinkedIn — https://ca.linkedin.com/in/thefoodprofessor The Food Professor Podcast — https://the-food-professor.simplecast.com/ Food Tech / Salmon AquaBounty — https://aquabounty.com/our-salmon/why-aquabounty-salmon FDA AquAdvantage Salmon Fact Sheet — https://www.fda.gov/animal-veterinary/aquadvantage-salmon/aquadvantage-salmon-fact-sheet Sustainable Blue — https://www.sustainableblue.com/ Canada Food Policy / Data Canada Grocery Code of Conduct — https://canadacode.org/ Code of Conduct Page — https://canadacode.org/code/code-of-conduct/ Health Canada Front-of-Package Nutrition Symbol — https://www.canada.ca/en/health-canada/services/food-nutrition/nutrition-labelling/front-package.html Statistics Canada Household Income — https://www.statcan.gc.ca/hub-carrefour/quality-life-qualite-vie/prosperity-prosperite/household-income-revenu-menage-eng.htm CUSMA — https://www.international.gc.ca/trade-commerce/trade-agreements-accords-commerciaux/agr-acc/cusma-aceum/index.aspx?lang=eng GST/HST Holiday Page — https://www.canada.ca/en/services/taxes/child-and-family-benefits/gst-hst-holiday-tax-break.html David Dodge, Bank of Canada Profile — https://www.bankofcanada.ca/profile/david-dodge/ Companies / Brands Mentioned Loblaw Companies — https://loblaw.ca/ Sobeys — https://www.sobeys.com/ Walmart Canada — https://www.walmartcanada.ca/ CBC Organization Profile — https://federal-organizations.canada.ca/profil.php?OrgID=CBC&lang=en Johnson & Johnson — https://www.jnj.com/ McDonald's Canada — https://www.mcdonalds.com/ca/en-ca.html GLP-1 / Weight Loss Drugs Ozempic Canada — https://www.ozempic.ca/en_ca.html Wegovy Canada — https://www.wegovy.ca/en_ca.html Media / Podcast Reference The Joe Rogan Experience — https://open.spotify.com/show/4rOoJ6Egrf8K2IrywzwOMk   Show Notes 00:00 Welcome to the Hart2Heart Podcast  00:37 Lab Meat Hype Cycle 01:50 How Cultured Meat Works 03:06 Acceptance and Cost Barriers 04:46 Taste Test and Nutrition Tweaks 06:54 Vegans Vegetarians and Labeling 14:53 Canada Food Inflation Debate 15:57 Grocers Fees and Supplier Squeeze 17:40 Policy Roots and Middle Class Squeeze 21:06 Fixes Without More Spending 23:27 Supply Management Price Premiums 24:51 Politics Crises and Inflation Spending 26:53 Inflation And Taxes 27:38 Conservative Policy Impact 28:19 Grocer Margins And Manufacturing 30:05 GST Holiday Backfire 33:18 Media Blind Spots 35:05 Counter Tariffs Price Ripple 37:41 Carney Versus Poilievre 42:53 Media Subsidies And CBC 44:39 Ultra Processed Food Debate 48:54 Addiction Obesity And GLP1 51:30 Regulation Tradeoffs Wrap Up 52:51 Where To Follow Closing   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

What if your company's biggest untapped competitive advantage isn't technology or talent, but well-being? In this episode, Brandon Laws sits down with Dr. Jennifer Posa, an organizational psychologist with 30 years of experience building well-being strategies inside some of the world's most demanding organizations, including Mayo Clinic, Johnson & Johnson, and the CIA. Jennifer shares her bold 2026 predictions for the workplace, explains why most well-being programs fail before they start, and reveals what it actually takes to build a strategy that drives real business results. From psychological contracts to the AI culture crisis brewing right now, this conversation is packed with insights that HR leaders, executives, and people managers can't afford to miss. If you care about the future of your workplace and who's going to be left standing after the next wave of disruption, this episode is essential listening. Key Timestamps [00:01] – Introduction & Jennifer's Unique Background Brandon introduces Dr. Jennifer Posa and her remarkable 30-year career in well-being at high-performing organizations including Mayo Clinic, Johnson & Johnson, and the CIA. [00:55] – When Well-Being Became a Strategy, Not a Perk Jennifer shares the personal and professional turning points that revealed well-being isn't just a "nice to have"—it's backed by decades of research showing measurable improvements in business outcomes. [03:03] – Lessons from the CIA: Well-Being in High-Stakes Environments What does well-being look like when the stakes couldn't be higher? Jennifer unpacks three powerful lessons from her role as Chief Well-Being Officer at the CIA, starting with the critical insight that well-being is individual—not prescriptive. [07:25] – Proactive vs. Reactive: The Well-Being Gap Most Employers Miss Brandon and Jennifer discuss why so many organizations wait for burnout, turnover, and absenteeism before taking action—and what a truly proactive approach looks like when it's embedded at the C-suite level. [08:27] – Prediction #1: Accountability Is the Differentiator in 2026 Jennifer's first 2026 prediction: organizations that hold themselves accountable for employee pain points will win. She breaks down what accountability actually looks like—hint: it's a business strategy, not a wellness app. [13:32] – How to Find the Real Pain Points (Not the Ones You Assume) Jennifer reveals her research-first approach—why she leads with qualitative focus groups before any survey, and how asking "what matters most to you?" unlocks a well-being strategy grounded in truth, not assumption. [17:59] – Prediction #2: Strategic Employee Relationships Drive Exceptional Growth Jennifer introduces the concept of the "psychological contract" and explains why every decision an employer makes right now is either building or breaking that unspoken agreement with their workforce. [21:32] – Scaling the Personal: Well-Being Across 140,000 Employees at J&J How do you make well-being feel personal inside an organization with 140,000 employees across 77 countries—during a global pandemic? Jennifer shares how J&J humanized their strategy at scale. [27:26] – Prediction #3: AI Is a Cultural Issue, Not Just a Technology Issue Jennifer's most provocative prediction: organizations that fail to address the human side of AI adoption will fracture their culture from the inside out. She explains why AI integration is one of the biggest C-suite conversations of our time. [31:45] – How to Prepare Your Workforce for an AI-Driven World Jennifer offers a practical framework for thinking about AI and humans as collaborative partners—and introduces the concept of "performance tradecraft" to help employees build the brain skills needed to thrive amid rapid change. [36:49] – Where to Connect with Dr. Jennifer Posa Brandon wraps up the conversation and Jennifer shares how listeners can follow her work, access her insights, and continue the conversation. A QUICK GLIMPSE INTO OUR PODCAST Podcast: Transform Your Workplace, sponsored by Xenium HR Host: Brandon Laws In Brandon's own words: "The Transform Your Workplace podcast is your go-to source for the latest workplace trends, big ideas, and time-tested methods straight from the mouths of industry experts and respected thought-leaders." About Xenium HR Xenium HR is on a mission to transform workplaces by providing expert outsourced HR and payroll services for small and medium-sized businesses. With a people-first approach, Xenium helps organizations create thriving work environments where employees feel valued and supported. From navigating compliance to enhancing workplace culture, Xenium offers tailored solutions that empower growth and simplify HR. Whether managing employee relations, payroll processing, or implementing impactful training programs, Xenium is the trusted partner businesses rely on to elevate their workplace experience. Discover how Xenium can transform your workplace: Learn more Connect with Brandon Laws: LinkedIn | Instagram | About Connect with Xenium HR: Website | LinkedIn | Facebook | Twitter | Instagram | YouTube

  Live from Sin City it's The Majority Report   On today's program:   While speaking on the Senate floor about Bernie Sanders' resolutions to block the transfer of bulldozers and weapons to Israel, Senator Chris Van Hollen (D-MD) highlights the story of Rachel Corrie, an American killed by an armored Israeli bulldozer. The resolution failed thanks to every single Republican and 7 Democrats - like Chuck Schumer and Kristen Gillibrand.   Scott Bessent claims that the tariff refunds are, thanks to the Supreme Court, going to China.   Sam hosts a series of interviews with lawyers from the firm Levin Papantonio the Mass Tort Conference in Las Vegas.   Glen Ged discusses his firms work on Internation Emergency Economic Powers Act tariff refunds.   Peter Mougey joins Sam for an update on his firms work on the opioid epidemic.   Chris Tisi joins Sam to discuss a mass tort case involving Johnson & Johnson and the toxicity of talcum powder.   Caleb Cunningham really piques Sam interest with his work on infections stemming from dirty scopes used in colonoscopies in a case near to Sam's...heart.   Rep. Jared Golden (D-ME) sabotages the war powers act vote.   Pete Hegseth recites a prayer that is stolen from Pulp Fiction. Hegseth also went on an antisemitic rant about the media during a pentagon briefing.   Tim Pool has a theory about women that really applies to him in an outrageous display of total projection.   All that and more   To connect and organize with your local ICE rapid response team visit ICERRT.com The Congress switchboard number is (202) 224-3121. You can use this number to connect with either the U.S. Senate or the House of Representatives. Follow us on TikTok here: https://www.tiktok.com/@majorityreportfm Check us out on Twitch here: https://www.twitch.tv/themajorityreport Find our Rumble stream here: https://rumble.com/user/majorityreport Check out our alt YouTube channel here: https://www.youtube.com/majorityreportlive Gift a Majority Report subscription here: https://fans.fm/majority/gift Subscribe to the AMQuickie newsletter here: https://am-quickie.ghost.io/ Join the Majority Report Discord! https://majoritydiscord.com/ Get all your MR merch at our store: https://shop.majorityreportradio.com/ Get the free Majority Report App!: https://majority.fm/app Go to https://JustCoffee.coop and use coupon code majority to get 10% off your purchase Check out today's sponsors: FAST GROWING TREES: Get 20% off your first purchase.  FastGrowingTrees.com/majority SUNSET LAKE: use coupon code 420 to save 30% sitewide at sunsetlakecbd.com The sale ends April 22nd at midnight Eastern time. Follow the Majority Report crew on Twitter: @SamSeder @EmmaVigeland @MattLech On Instagram: @MrBryanVokey Check out Matt's show, Left Reckoning, on YouTube, and subscribe on Patreon! https://www.patreon.com/leftreckoning Check out Matt Binder's YouTube channel: https://www.youtube.com/mattbinder Subscribe to Brandon's show The Discourse on Patreon! https://www.patreon.com/ExpandTheDiscourse Check out Ava Raiza's music here! https://avaraiza.bandcamp.com

This episode covers: Cardiology This Week: A concise summary of recent studies Time for physiological pacing in heart failure? Same-day discharge after EP procedures: from evidence to practice EHRA 2026 Scientific Highlights Host: Gerd Hindricks Guests: Haran Burri, Emma Svennberg, Julia Vogler Want to watch that episode? Go to: https://esc365.escardio.org/event/2555    Disclaimer ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video.  The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honorary from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Gerd Hindricks has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson. Julia Vogler has declared to have potential conflicts of interest to report: honoraria for talks: Abbott.

US results season opens with Goldman Sachs and Johnson & Johnson both beating expectations — but the more interesting story is what those results don't show yet: the full impact of Middle East conflict and Trump's drug pricing pressure. Simon also unpacks South Africa's looming fuel crisis and makes the economic case for working from home, a new 100% offshore ETF listing on the JSE from ETFSA, and an ASP Isotopes update for those holding a speculative position. FNB's FCA-mandated R11.9bn provision for undisclosed UK vehicle finance commissions gets a full breakdown, as does the nuanced reality of the Straits of Hormuz "blockade" — it has T's and C's. Plus a long-overdue Bitcoin check-in. WorldWideMarkets is part of JustOneLap.com.

Discover how mindfulness can transform your daily life, reduce stress, and help you find joy amidst chaos, especially for widows and widowers navigating grief, careers, and parenting. Harriet Stein shares practical insights, her personal story, and tools to incorporate mindfulness into busy routines.   Key topics: The true meaning of mindfulness: paying attention without judgment Practical ways to practice mindfulness in everyday activities like driving, washing hands, and walking How mindfulness can ease stress and grief, especially during challenging times The nine attitudes of mindfulness according to John Kabat-Zinn Harriet's journey from nursing to coaching, and writing her book, Perfect Attendance The importance of being present for life, not work, as highlighted in Harriet's story about her mother Easy resources for beginners: books, YouTube channels, and mindfulness practices The value of daily mindfulness practices like pause, gratitude, and sensory awareness   Timestamps: 00:00 - Introduction to mindfulness and its relevance for widows and widowers 00:29 - The definition of mindfulness: paying attention without judgment 00:59 - How to practice mindfulness in daily life: red lights, walking, and chores 02:01 - Harriet's personal journey from nurse to mindfulness coach 03:20 - Incorporating mindfulness in corporate settings: stress reduction and focus 04:05 - Simple exercises to develop mindfulness: noticing thoughts and sensations 06:20 - Lessons learned from Harriet's grief process and its duration 07:43 - Strategies for maintaining mindfulness with busy schedules and grief 08:05 - The nine attitudes of mindfulness, with an emphasis on non-striving 11:17 - Harriet's book: Perfect Attendance, Being Present for Life 13:01 - The story behind the book's title and the importance of presence over work 14:05 - Clarifying myths about mindfulness and its practical application 17:23 - Practical resources: books, online courses, and community practices 18:49 - Incorporating mindfulness into daily transitions and breaks 20:19 - The significance of sensory-grounding techniques, like hand-washing, for stress relief 21:56 - Recommended mindfulness resources: Jon Kabat-Zinn, YouTube channels, and retreats 23:38 - Harriet's website: harrietstein.com and how to connect 24:23 - Words of wisdom: you are enough, and authenticity matters 25:35 - Final encouragement to prioritize self-care through mindfulness     Connect with Harriet Stein: Website: harrietstein.com   More about Harriet Stein  HARRIET STEIN, RN, MS Harriet Stein understands the unique challenges that businesses face today. An inspirational teacher and professional speaker, Harriet is passionate about speaking to organizations of all sizes about how a culture of mindfulness can reduce stress, increase performance, lower healthcare costs, and boost employee engagement. A cookie-cutter app cannot effectively show you how to use mindfulness to combat work overload, answer your specific questions, or address your unique challenges. Harriet's mindfulness programs teach essential skills through hands-on instruction that provides practical tools for achieving a more fulfilling and productive life. Harriet is the author of Perfect Attendance: Being Present for Life and creator of Take a Pause, the award-winning international mindfulness training program that won first place in Impact on the Organization and second place in Innovation and Creativity at Sindusfarma's Boomerang Awards, which recognize the best-in-class training and development programs in the pharmaceutical industry in Brazil. She has extensive experience teaching mindfulness practices and strategies at Fortune 500 companies to improve corporate culture. During her tenure at Johnson & Johnson, she used her expertise and passion to directly instruct more than 5,000 worldwide employees on the practice of mindfulness through engaging programs and at leadership summits. Mixing research and science with levity and fun, Harriet's proven strategies teach tangible ways to live in the present and be accessible, both professionally and personally. Learn how to reduce stress, increase patience, and create space in your life to accomplish what you want to achieve – more creativity, more efficiency, or just a better night's sleep! Harriet's first teacher was Dr. Jon Kabat-Zinn, founder of Mindfulness-Based Stress Reduction. She completed extensive professional training at the Myrna Brind Center for Mindfulness at Thomas Jefferson University Hospital. This advanced training, interwoven with her background as a Registered Nurse and her Master of Science degree in Health Administration, is foundational to the compassion and purpose she brings to her mindfulness programs.   _______________________________ CONNECT with Donna Jean Kendrick Facebook: @donnajeankendrick  LinkedIn: linked.com/in/donna-kendrick  Instagram: @donnajeankendrick Website: https://sephtonfinancial.com/  Phone: (215) 948-3945 Complimentary Consultation/Contact Us: https://sephtonfinancial.com/contact/  Downloadables and Resources: https://sephtonfinancial.com/resources/  _______________________________ Donna Kendrick is a Certified Financial Planner and Certified Divorce Financial Analyst and owner of Sephton Financial located at 314 Washington Ln, Jenkintown, PA 19046. If you'd like to contact Sephton Financial you can do so online at SephtonFinanical.com or by calling 215 948 3945 Registered Representative offering securities through Cetera Financial Specialists LLC, member FINRA/SIPC. Advisory services are offered through Cetera Investment Advisers LLC. Cetera is under separate ownership from any other named entity. Sephton Financial, LLC and Cetera are not affiliated. The views depicted in this material are for information purposes only and are not necessarily those of Sephton Financial. They should not be considered specific advice or recommendations for any individual. Neither Sephton Financial nor any of its representatives may give legal or tax advice. The guests on the podcast are not affiliated or registered with Cetera Financial Specialist. Any information provided by the guests are in no way related to Cetera Financial Specialist or its registered representatives.  

This time on CodeWACK! Most employers don't actually know what they're paying for healthcare - and employees are paying the price. In this episode of Code WACK!, discover why companies are "flying blind" on healthcare costs, how opaque pricing drives higher premiums, and what this means for your coverage, care, and financial security. To learn more, we spoke with Chuck Melendi, who has more than three decades of experience in healthcare leadership, advocacy, and industry strategy. He spent 25 years at Johnson & Johnson, where he tackled issues including drug pricing, payer negotiations, policy, and commercial strategy. Chuck retired from Johnson & Johnson in early 2025 and went on to launch Disruptive Dialogue, a podcast and consulting platform where he shares insights from inside the U.S. healthcare system – while exploring ideas for reform. This is the second of a two-part series. Check out the Transcript and Show Notes for more! And please keep Code WACK! on the air with a tax-deductible donation at heal-ca.org/donate.

What happens when a Division I athlete, 10-year Johnson & Johnson executive, and 12-year real estate veteran builds a FinTech platform to connect private capital to real estate operators at scale?   You get Douglas J. Beck — and this conversation is a masterclass in creative capital markets, PropTech innovation, and how serious operators like Vinney are structuring deals that generate 22% IRR for their investors.   In this episode of Syndication Made Easy, Vinney "Smile" Chopra sits down with Douglas to break down his AI-powered loan matching platform, his vision of a private lender affiliate army, and how syndicators can tap into an entirely new channel of capital — without competing deal by deal.  

This time on CodeWACK! What challenges do employers face when providing health coverage to their employees? And what role do health insurers and Pharmacy Benefit Managers - prescription drug middlemen known as PBMs—play in shaping costs, coverage, and access to care? To find out, we spoke with Chuck Melendi, who has more than three decades of experience in healthcare leadership, advocacy, and industry strategy. He spent 25 years at Johnson & Johnson, where he tackled issues including drug pricing, payer negotiations, policy, and commercial strategy. Chuck retired from Johnson & Johnson in early 2025 and went on to launch Disruptive Dialogue, a podcast and consulting platform where he shares insights from inside the U.S. healthcare system – while exploring ideas for reform. This is the first of a two-part series.  Check out the Transcript and Show Notes for more! 

Description: Learn why advocating for care is crucial when moderate to severe plaque psoriasis develops at a young age or in high-impact sites, and how advanced biologic therapies can offer effective solutions for those that may be undertreated. Join moderator Kaitlin Walden, patient advocate Carolyn, and dermatologist Dr Candrice Heath as they discuss the realities of living with moderate to severe plaque psoriasis at a young age, as well as adult patients with plaque psoriasis in high-impact sites, like the scalp, nails, and face. Carolyn shares her personal journey with moderate to severe plaque psoriasis and how it has continued from childhood into adulthood, while Dr Heath offers insights to help caregivers and patients navigate treatment approaches, including when and how a biologic therapy may be helpful. This episode addresses challenges associated with living and treating moderate to severe plaque psoriasis in children and adults. This episode is sponsored by Johnson & Johnson. Please see Important Safety Information and full Prescribing Information for the product mentioned in this episode. Timestamps: ·       (0:23) Intro to Psoriasis Uncovered and guest introductions from dermatologist Dr. Candrice Heath and Carolyn, a patient advocate living with plaque psoriasis and psoriatic arthritis. ·       (1:22) Information about, and pivotal data for, TREMFYA® (guselkumab), a biologic used to treat adults and children 6 years and older who weigh at least 88 lbs or 40 kilograms with moderate to severe plaque psoriasis. ·       (3:48) Living with psoriasis as a child can be difficult with challenges in being diagnosed correctly and receiving appropriate treatment.  ·       (6:17) A dermatologist's view of children and adolescents living with plaque psoriasis including in high-impact sites. ·       (8:14) It's important to advocate for yourself and the best possible care. ·       (9:37) Open communication with your dermatologist helps identify the best possible treatment plan, which is dependent on several factors including the availability of new treatment options. ·       (12:05) Carolyn's biggest challenge is managing her psoriasis and then psoriatic arthritis. ·       (14:20) Results of the SPECTREM clinical trial addressing treatment of adults with moderate plaque psoriasis in high-impact sites. ·       (17:38) Find the support and information you need to find the right treatment. ·       (21:48) Important Safety Information about TREMFYA® (guselkumab).   Key Takeaways: ·       Plaque psoriasis can be challenging both physically and emotionally for children and adults – especially when high-impact site involvement (such as the face, scalp, armpits, and groin) is present. ·       Individual treatment plans vary and are based on several factors, including the severity of psoriasis, dosing schedule, cost, or route of administration. Finding the right treatment for plaque psoriasis is a collaboration between a dermatologist, the patient, and/or family (should the patient be a child). ·       A number of medicines that treat plaque psoriasis from the inside out, including biologics, are now available for children and adults. Such treatment options are continuing to expand. Guest Bios: Candrice Heath, M.D. is a highly respected triple board-certified dermatologist who sees both children and adults at Howard University Hospital in Washington DC where she is also an Associate Professor in the Department of Dermatology. She is board-certified in dermatology, pediatrics, and pediatric dermatology.  Dr Heath is a nationally recognized speaker, pediatric and adult dermatology clinical researcher, and has held a variety of leadership roles including Chair for the Pediatric Dermatology Research Alliance (PeDRA), Skin of Color and Pigmentary Disorders Focused Group, Skin of Color Society National Secretary-Treasurer, and American Academy of Dermatology Diversity Committee member. Her clinical, research, and teaching interests are shaped by insights gained from her unique practice filled with both children and adults in addition to her passion for exploring the intersection of dermatology and social science.  Carolyn Pugh is a patient advocate and volunteer with the National Psoriasis Foundation who lives with psoriasis and psoriatic arthritis. Carolyn was diagnosed with psoriasis at age 11 after being misdiagnosed and offered treatments that didn't work. Once she was diagnosed with plaque psoriasis some of the initial treatments were difficult and unsustainable. Over the years she has learned to advocate for her own self-care and feels her personal experiences can help empower other adults and parents. Resources: ·       Learn more about treatment options for children and adolescents at Our Spot for Youth and Parents   ·       For more information about psoriasis in high-impact sites